<DOC>
	<DOC>NCT01723878</DOC>
	<brief_summary>This observational study will evaluate the patterns of disease progression in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring EGFR activating mutations receiving Tarceva (erlotinib) as first-line treatment. Patients will be followed for up to 12 months after progression of disease.</brief_summary>
	<brief_title>ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Histologically or cytologically confirmed locally advanced or metastatic (IIIB/IV) nonsquamous nonsmall cell lung cancer (NSCLC) which is routinely evaluated in clinical practice according to RECIST criteria EGFR mutationpositive disease according to local laboratory testing Patients on treatment with Tarceva monotherapy as firstline treatment according to the physician's usual practice Prior systemic therapy for advanced NSCLC. The administration of neoadjuvant or adjuvant chemotherapy is allowed as long as it was finalized &gt;6 months prior to receiving Tarceva Participation in another clinical study Patients could have received radiotherapy as long as the irradiated lesion was not the only lesion for evaluating response and a long as the radiotherapy was completed before initiating Tarceva treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>